Headlines about Diplomat Pharmacy (NYSE:DPLO) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Diplomat Pharmacy earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.1562620962634 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern’s rankings:
A number of research analysts have commented on the company. Barclays assumed coverage on Diplomat Pharmacy in a research note on Thursday, March 8th. They issued an “overweight” rating and a $27.00 target price on the stock. Deutsche Bank downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating and boosted their target price for the company from $22.00 to $29.00 in a research note on Friday, February 2nd. Lake Street Capital assumed coverage on Diplomat Pharmacy in a research note on Friday, February 9th. They issued a “buy” rating and a $35.00 target price on the stock. Credit Suisse Group upgraded Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 target price on the stock in a research note on Thursday, January 25th. Finally, Leerink Swann set a $30.00 target price on Diplomat Pharmacy and gave the company a “buy” rating in a research note on Tuesday, February 27th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $25.38.
Shares of DPLO traded down $0.42 during trading hours on Friday, hitting $19.72. 499,137 shares of the company were exchanged, compared to its average volume of 845,807. The company has a market cap of $1,491.75, a PE ratio of 23.48 and a beta of 1.32. Diplomat Pharmacy has a 52 week low of $14.00 and a 52 week high of $27.78. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.66 and a current ratio of 0.97.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Monday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.02. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a return on equity of 8.89% and a net margin of 0.35%. The firm’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.08 EPS. research analysts predict that Diplomat Pharmacy will post 0.94 earnings per share for the current year.
In related news, Director Philip R. Hagerman sold 2,150,000 shares of the business’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $20.65, for a total transaction of $44,397,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 30.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Diplomat Pharmacy (NYSE:DPLO) Given Daily News Impact Score of 0.19” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/diplomat-pharmacy-dplo-getting-somewhat-favorable-news-coverage-report-finds.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.